RecruitingPhase 2NCT00409435

A Study of Pyridostigmine in Postural Tachycardia Syndrome

Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome

Sponsor

Mayo Clinic

Enrollment

50 participants

Start Date

Oct 1, 2006

Study Type

INTERVENTIONAL

Conditions

Postural Tachycardia Syndrome

Summary

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Eligibility

Min Age: 15 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called pyridostigmine for people with postural tachycardia syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 15 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.